SEC Form 4
CG Oncology, Inc. (CGON) insider trading
In the 12 months to Oct 26, 2026, 2 CGON insiders reported open-market sales of $4.8M across 13 filings; one director bought $24.8M.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $4.8M
- 13 filings · 2 insiders
- Open-market purchases
- $24.8M
- 1 filing · Brian Guan-Chyun Liu, Director
- Pre-arranged sales (10b5-1)
- 13 of 13
- All $4.8M sold was pre-arranged
Who traded CGON, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
CGON daily close from Oct 27, 2025 to Oct 26, 2026, between $37.37 and $80.68, last $61.51. 13 sale and 1 purchase filings by 3 insiders, marked at their filing dates. Brian Guan-Chyun Liu, Director: bought $24.8M across 1 filing, first filed Jun 29, 2026, last Jun 29, 2026. James Mulay, Director: sold $3.8M across 5 filings, first filed Jan 13, 2026, last Jul 14, 2026. Leonard E. Post, Director: sold $1.1M across 8 filings, first filed Nov 18, 2025, last Oct 19, 2026.
Largest mark · tap a row for others
Brian Guan-Chyun Liu · Director
Purchase $24,814,454
371,085 shares at $66.87 avg
Filed Jun 29, 2026 · traded Jun 25
Pre-arranged (10b5-1) · close on filing date $73.73
Brian Guan-Chyun Liu · Director
Director
$24.8M boughtJames Mulay · Director
Director
$3.8M soldLeonard E. Post · Director
Director
$1.1M soldOpen-market trades
14 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Brian Guan-Chyun Liu | Director | — | $24.8M | 1 | — | |
| James Mulay | Director | $3.8M | — | 5 | 100% of sales | |
| Leonard E. Post | Director | $1.1M | — | 8 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Leonard E. Post Director | SalePre-arranged (10b5-1) | 1,000 | $62.07 | $62.1K | 0 | |
traded | Leonard E. Post Director | SalePre-arranged (10b5-1) | 1,000 | $72.98 | $73.0K | 0 | |
traded | Leonard E. Post Director | SalePre-arranged (10b5-1) | 1,000 | $74.54 | $74.5K | 0 | |
traded | Leonard E. Post Director | SalePre-arranged (10b5-1) | 1,000 | $71.17 | $71.2K | 0 | |
traded | James Mulay Director | SalePre-arranged (10b5-1) | 24,165 | $75.16 | $1.8M | 0 | |
traded | Brian Guan-Chyun Liu Director | PurchasePre-arranged (10b5-1) | 371,085 | $66.87 | $24.8M | 1,886,236 | |
traded | Leonard E. Post Director | SalePre-arranged (10b5-1) | 5,000 | $70.00 | $350.0K | 0 | |
traded | Leonard E. Post Director | SalePre-arranged (10b5-1) | 5,000 | $65.00 | $325.0K | 0 | |
traded | James Mulay Director | SalePre-arranged (10b5-1) | 1,964 | $60.12 | $118.1K | 0 | |
traded | Leonard E. Post Director | SalePre-arranged (10b5-1) | 1,000 | $54.50 | $54.5K | 0 | |
traded | James Mulay Director | SalePre-arranged (10b5-1) | 15,600 | $73.01 | $1.1M | 0 | |
traded | James Mulay Director | SalePre-arranged (10b5-1) | 1,964 | $63.50 | $124.7K | 0 | |
traded | James Mulay Director | SalePre-arranged (10b5-1) | 11,145 | $52.47 | $584.8K | 0 | |
traded | Leonard E. Post Director | SalePre-arranged (10b5-1) | 1,000 | $41.43 | $41.4K | 0 |
GET /stocks/filings/vX/form-4?tickers=CGON&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"CGON"
],
"issuer_cik": "0001991792",
"owner_cik": "0001235862",
"accession_number": "0001193125-26-425295",
"form_type": "4",
"filing_date": "2026-10-19",
"period_of_report": "2026-10-15",
"issuer_name": "CG Oncology, Inc.",
"issuer_trading_symbol": "CGON",
"owner_name": "POST LEONARD E",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-15",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 500,
"transaction_price_per_share": 61.65,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 500,
"transaction_value": 30825,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026."
},
{
"id": "F2",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.16 to $62.06 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."
}
]
},
{
"tickers": [
"CGON"
],
"issuer_cik": "0001991792",
"owner_cik": "0001235862",
"accession_number": "0001193125-26-425295",
"form_type": "4",
"filing_date": "2026-10-19",
"period_of_report": "2026-10-15",
"issuer_name": "CG Oncology, Inc.",
"issuer_trading_symbol": "CGON",
"owner_name": "POST LEONARD E",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-15",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 500,
"transaction_price_per_share": 62.48,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 0,
"transaction_value": 31240,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026."
},
{
"id": "F3",
"description": "The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.27 to $62.60 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 20 records
- Option exercises18 records
- Tax withholding2 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has CG Oncology, Inc.'s CEO sold stock?
No. Arthur Kuan (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is CGON’s insider data?
These are CGON Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track CGON insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for CGON every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.